Publicacións en colaboración con investigadores/as de Hospital General de Elda (2)

2010

  1. Adjuvant docetaxel for high-risk, node-negative breast cancer

    New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210

2004

  1. Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: Results of a large, multicentre phase II study

    Cancer Chemotherapy and Pharmacology, Vol. 53, Núm. 1, pp. 75-81